Fatma El Zahraa Gamal
Research Subjects
Fatma El Zahraa Gamal has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Fatma M. Gadallah2 shared publications
- Afaf A. Khedr
Central Laboratory for Evaluation of Veterinary Biologics (CLEVB), Abbasia, Cairo, Egypt
1 shared publication - Dalia M. Omar1 shared publication
- Heba M.G. Abd El-Aziz
Agriculture Research Center, Central Laboratory for Evaluation of Veterinary Biologics, El-Seka-Baida Street, Abbasia, Cairo, Egypt
1 shared publication - Lamiaa Mohamed Omar1 shared publication
- Marwa Salah Eldin Diab1 shared publication
Latest Publications
- Open Access
- 30 June 2026
- Published by Scienceline Publication in World's Veterinary Journal
- Vol. 16 (2) , 508
Genotypic Characterization of Escherichia coli Pathotypes Based on Antibiotic Resistance Genes
Diarrhea represents a major health challenge in young calves and is a leading cause of mortality, arising from infectious and non-infectious factors. The present study aimed to investigate antibiotic-resistant, multi-virulent diarrheagenic Escherichia coli (E. coli) strains isolated from human and animal samples. The current study included 23 E. coli strains obtained from calves across four different farms in Egypt, as well as nine E. coli isolates derived from 18 stool samples from workers. These samples were transferred to the microbiological laboratory for bacteriological and molecular analysis utilizing polymerase chain reaction (PCR). Molecular analysis of the antibiotic resistance gene was performed using PCR, followed by antibiotic sensitivity testing against ciprofloxacin, enrofloxacin, norfloxacin, ampicillin, cephalosporin, and colistin. Among 23 E. coli isolates obtained from calves, the resistance genes, including qnrS (21.7%), gyrA (34.7%), and blaTEM (13%), were identified. Conversely, qnrA, blaOXA-1, and blaSHV were not detected. Only one isolate exhibited colistin resistance, which was uncommon. Human E. coli isolates demonstrated moderate prevalence of qnrA (55.5%), qnrS (33.3%), gyrA (33.3%), and blaTEM (22.2%), while blaOXA and blaSHV were not detected, and a colistin resistance isolate (mcr-1) was rare. The antibiotic sensitivity test of E. coli isolates from calves exhibited that 43% were resistant to ciprofloxacin and 35% to enrofloxacin. Meanwhile, 22% of isolates demonstrated resistance to norfloxacin. The β-lactam group revealed 13% resistance to ampicillin and cephalosporin. Only 4% of all isolates exhibited resistance to colistin. Antibiotic sensitivity test of E. coli isolates from humans revealed significant resistance patterns. Among the quinolones, 78% demonstrated resistance to ciprofloxacin, 56% to enrofloxacin, and 45% to norfloxacin. In contrast, only 22% of isolates were resistant to ampicillin and cephalosporin, while resistance to colistin was detected in just 11% of isolates. The present study confirmed that the misuse of different antibiotics is a significant factor in the development of antimicrobial resistance genes, especially in E. coli strains isolated from both humans and infected calves.
- 30 June 2026
- Published by Scienceline Publication in World's Veterinary Journal
- Vol. 16 (2) , 508
Open AccessGenotypic Characterization of Escherichia coli Pathotypes Based on Antibiotic Resistance Genes
Diarrhea represents a major health challenge in young calves and is a leading cause of mortality, arising from infectious and non-infectious factors. The present study aimed to investigate antibiotic-resistant, multi-virulent diarrheagenic Escherichia coli (E. coli) strains isolated from human and animal samples. The current study included 23 E. coli strains obtained from calves across four different farms in Egypt, as well as nine E. coli isolates derived from 18 stool samples from workers. These samples were transferred to the microbiological laboratory for bacteriological and molecular analysis utilizing polymerase chain reaction (PCR). Molecular analysis of the antibiotic resistance gene was performed using PCR, followed by antibiotic sensitivity testing against ciprofloxacin, enrofloxacin, norfloxacin, ampicillin, cephalosporin, and colistin. Among 23 E. coli isolates obtained from calves, the resistance genes, including qnrS (21.7%), gyrA (34.7%), and blaTEM (13%), were identified. Conversely, qnrA, blaOXA-1, and blaSHV were not detected. Only one isolate exhibited colistin resistance, which was uncommon. Human E. coli isolates demonstrated moderate prevalence of qnrA (55.5%), qnrS (33.3%), gyrA (33.3%), and blaTEM (22.2%), while blaOXA and blaSHV were not detected, and a colistin resistance isolate (mcr-1) was rare. The antibiotic sensitivity test of E. coli isolates from calves exhibited that 43% were resistant to ciprofloxacin and 35% to enrofloxacin. Meanwhile, 22% of isolates demonstrated resistance to norfloxacin. The β-lactam group revealed 13% resistance to ampicillin and cephalosporin. Only 4% of all isolates exhibited resistance to colistin. Antibiotic sensitivity test of E. coli isolates from humans revealed significant resistance patterns. Among the quinolones, 78% demonstrated resistance to ciprofloxacin, 56% to enrofloxacin, and 45% to norfloxacin. In contrast, only 22% of isolates were resistant to ampicillin and cephalosporin, while resistance to colistin was detected in just 11% of isolates. The present study confirmed that the misuse of different antibiotics is a significant factor in the development of antimicrobial resistance genes, especially in E. coli strains isolated from both humans and infected calves.
- Open Access
- 1 January 2025
- Published by AVES YAYINCILIK A.Ş. in Acta Veterinaria Eurasia
- Vol. 51 (1) , 1-7
Immunological Study on Chickens Vaccinated with a Trivalent Combined Inactivated Mycoplasma gallisepticum, Escherichia coli, and Newcastle Disease Virus (ND) Vaccine
Vaccination is a key control measure for most avian diseases, including the endemic Newcastle disease (ND), Mycoplasmosis, and Colibacillosis in Egypt. This study evaluated three inactivated monovalent commercial vaccines, one for each infection, and an inactivated trivalent locally prepared vaccine for the same diseases. The evaluation included challenge tests for the three diseases and monitoring of antibody levels using the hemagglutination inhibition test for ND and Enzyme-Linked Immunosorbent Assay (ELISA) for Mycoplasmosis. The trivalent vaccine showed protective percentages of 100%, 80%, and 80% against the three diseases, respectively. The monovalent commercial vaccines provided protections of 100%, 70%, and 70%, respectively. Hemagglutinating antibody titers for the trivalent vaccine were 6.9 and 6.5 log 2 at the second-week post-vaccination for LaSota and GVII antigens, respectively. In comparison, the monovalent commercial vaccine showed 4 log 2 at the first-week post-vaccination for LaSota antigen and 6.7 log 2 at the second-week post-vaccination for GVII antigen. The ELISA antibody titers for Mycoplasmosis in both trivalent and monovalent vaccines increased gradually from the first-week post-vaccination (1043 and 987) to peak at the seventh-week post-vaccination (2266 and 2226), respectively. In conclusion, the inactivated trivalent vaccine against ND, Mycoplasmosis, and Colibacillosis demonstrated high potency, efficacy, and safety. Cite this article as: Omar, D. M., Gadallah, F. M., Abdrabo, M. A., Gamal, F. E., Monir, N. M., Gamil, M. A. , Abdel Rahman, M. A. A., Marden, N. A., Abu Zaid, R. A., Abd El-Aziz, H. M. G., Khedr, A. A., & Omar, L. M. (2025). Immunological study on chickens vaccinated with a trivalent combined inactivated Mycoplasma gallisepticum, Escherichia coli, and newcastle disease virus (ND) vaccine. Acta Veterinaria Eurasia, 2025, 51, 0014, doi: 10.5152/actavet.2025.25014.
- 1 January 2025
- Published by AVES YAYINCILIK A.Ş. in Acta Veterinaria Eurasia
- Vol. 51 (1) , 1-7
Open AccessImmunological Study on Chickens Vaccinated with a Trivalent Combined Inactivated Mycoplasma gallisepticum, Escherichia coli, and Newcastle Disease Virus (ND) Vaccine
Vaccination is a key control measure for most avian diseases, including the endemic Newcastle disease (ND), Mycoplasmosis, and Colibacillosis in Egypt. This study evaluated three inactivated monovalent commercial vaccines, one for each infection, and an inactivated trivalent locally prepared vaccine for the same diseases. The evaluation included challenge tests for the three diseases and monitoring of antibody levels using the hemagglutination inhibition test for ND and Enzyme-Linked Immunosorbent Assay (ELISA) for Mycoplasmosis. The trivalent vaccine showed protective percentages of 100%, 80%, and 80% against the three diseases, respectively. The monovalent commercial vaccines provided protections of 100%, 70%, and 70%, respectively. Hemagglutinating antibody titers for the trivalent vaccine were 6.9 and 6.5 log 2 at the second-week post-vaccination for LaSota and GVII antigens, respectively. In comparison, the monovalent commercial vaccine showed 4 log 2 at the first-week post-vaccination for LaSota antigen and 6.7 log 2 at the second-week post-vaccination for GVII antigen. The ELISA antibody titers for Mycoplasmosis in both trivalent and monovalent vaccines increased gradually from the first-week post-vaccination (1043 and 987) to peak at the seventh-week post-vaccination (2266 and 2226), respectively. In conclusion, the inactivated trivalent vaccine against ND, Mycoplasmosis, and Colibacillosis demonstrated high potency, efficacy, and safety. Cite this article as: Omar, D. M., Gadallah, F. M., Abdrabo, M. A., Gamal, F. E., Monir, N. M., Gamil, M. A. , Abdel Rahman, M. A. A., Marden, N. A., Abu Zaid, R. A., Abd El-Aziz, H. M. G., Khedr, A. A., & Omar, L. M. (2025). Immunological study on chickens vaccinated with a trivalent combined inactivated Mycoplasma gallisepticum, Escherichia coli, and newcastle disease virus (ND) vaccine. Acta Veterinaria Eurasia, 2025, 51, 0014, doi: 10.5152/actavet.2025.25014.